Deals


  • Johnson & Johnson's pharmaceutical office in Madrid, Spain.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    J&J bets $2.2B on Ollin’s vision loss drug

    The deal hands J&J a treatment that could complement its existing eye care franchise, but would vie for share of a crowded and competitive market.

    By • Nov. 16, 2026
  • A white sign with the word Lilly written in red stands outside of an office.
    Image attribution tooltip
    Scott Olson via Getty Images
    Image attribution tooltip

    Lilly adds to buyout streak with $1.5B purchase of startup Calytrix

    Lilly’s 15th announced acquisition this year — by far the most in the biopharmaceutical sector — centers around a precision therapy for rare blood disorders known as myeloproliferative neoplasms.

    By • Nov. 16, 2026
  • Glucagon-like peptide 1 (GLP1, 7-36) molecule The glucagon like peptide-1 receptor has a strong effect on the management of type 2 diabetes mellitus.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Obesity drugs

    Blackstone bets $1.5B on Pfizer’s obesity drug

    The deal will support a sprawling Phase 3 program for a monthly GLP-1 shot Pfizer acquired by winning a bidding war for the drug’s previous owner, Metsera.

    By • Nov. 12, 2026
  • A drop of liquid is held via a pipette above a row of vials.
    Image attribution tooltip
    deliormanli via Getty Images
    Image attribution tooltip

    Argenx to buy peptide platform in potentially billion-dollar deal

    For $550 million up front, Argenx will take control of Unnatural Products’ “macrocyclic peptide” technology and direct it to develop oral, durable medicines for serious immune-mediated diseases.

    By • Nov. 9, 2026
  • A Chapter 11 bankruptcy court document, with a pen under the word "bankruptcy."
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Karyopharm, deep in debt, to sell itself in bankruptcy

    The parent of cell therapy maker Gamida Cell will be the lead bidder in a court-supervised auction of Karyopharm, which recently cut a forbearance deal to push off debt payments.

    By • Nov. 2, 2026
  • Spermatozoon is injected into an ovum with help of microneedle and holding pipette underneath a microscope
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Ferring to acquire next-gen IVF startup Gameto for up to $1.4B

    The buyout hands Ferring rights to a technology capable of simplifying the lengthy and burdensome process of in vitro fertilization.

    By • Updated Oct. 28, 2026
  • Exterior building picture of the Merck KGaA Life Science site in Burlington, U.S.
    Image attribution tooltip
    Courtesy of Merck KGaA
    Image attribution tooltip

    Merck KGaA bets on RNAi with $1.3B Silence buyout

    The acquisition gives the German company a promising blood disorder medicine that passed a Phase 2 test and could threaten a Takeda drug.

    By • Oct. 19, 2026
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Roche inks $15B ADC pact with Hansoh; Veradermics scores in another baldness study

    Roche is paying Hansoh $400 million up front in a broad deal involving several ADCs. Elsewhere, another top investor formed a China-focused fund and Ultragenyx sold a second review voucher.

    By BioPharma Dive staff • Oct. 19, 2026
  • A double exposure photo illustration of a glass flask and a scientist holding a tube in a laboratory, with stock market information in the background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    This week in charts

    This week in charts: Moderna’s massive stock run

    The latest installment in BioPharma Dive’s data visualization-focused series includes a look at Moderna’s meteoric rise in 2026 and a sudden deal surge from Roche.

    By • Oct. 16, 2026
  • An illustration of engineered CAR-T cells attacking a cancer cell.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Belgian startup revives Galapagos CAR-T research

    Armed Cell Therapeutics, chaired by former Galapagos CEO Paul Stoffels, has assumed control of cell therapies the company — now known as Lakefront Biotherapeutics — divested in a strategic overhaul.

    By • Oct. 15, 2026
  • A photo of Wall Street in New York City in 2022.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Another Paragon spinout goes public through reverse merger

    One lawyer involved noted how it's yet another example of Paragon and key investor Fairmount — which have helped transform the reputation for reverse mergers — quickly executing on a complicated deal.

    By • Oct. 13, 2026
  • The exterior of the building housing the headquarters of Roche France, French subsidiary of the Swiss pharmaceutical group.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    China competition

    Roche extends China deal streak with $1B pact for RNAi obesity drug

    An alliance with Rona Therapeutics adds to a particularly active stretch for Roche and makes the company the latest to bet on medicines that can lower levels of “visceral” fat.

    By • Oct. 13, 2026
  • A corporate building is seen with a sign for the company Viatris
    Image attribution tooltip
    Courtesy of Viatris
    Image attribution tooltip

    Viatris boosts pain drug portfolio with $1.7B buyout of Pacira

    The deal hands Viatris two non-opioid pain treatments that booked nearly $700 million in 2025 but could soon lose patent protection. Viatris vowed to use its “intellectual property expertise” to sustain sales.

    By • Oct. 8, 2026
  • Front view of the NASDAQ MarketSite, which occupies the northwest corner at the base of the 4 Times Square building, in Midtown Manhattan, New York City.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Emerging biotech

    In the hunt for reverse merger targets, Caribou could be prized game

    The struggling cell therapy developer is exploring strategic alternatives, which, among other characteristics, make it a likely candidate to receive reverse merger interest.

    By • Oct. 8, 2026
  • A scientist in white jacket operates radiopharmaceutical manufacturing equipment.
    Image attribution tooltip
    Courtesy of GE HealthCare
    Image attribution tooltip

    GE HealthCare to acquire Sofie Biosciences for $945M

    The purchase expands GE HealthCare’s radiopharmaceutical capabilities, helping manufacture and distribute time-sensitive drugs used in PET imaging.

    By Susan Kelly • Oct. 6, 2026
  • Wall Street buildings
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Shionogi pays $2B to acquire a rare disease startup

    The acquisition of Texas-based IntraBio adds to a growing rare disease business for Shionogi by handing the company a marketed treatment for two inherited conditions.

    By • Oct. 5, 2026
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Optogenetics researchers win a Nobel Prize; Roche bets on Alector brain drug

    The Nobel laureates “laid the foundation” for a new field of brain research, the award committee wrote. Elsewhere, Roche and CSL cut licensing deals and the FDA endorsed broader use of a Lilly medicine.

    By • Oct. 5, 2026
  • A photo of Sanofi headquarters in Paris, France.
    Image attribution tooltip
    Courtesy of Sanofi
    Image attribution tooltip

    Sanofi, Regeneron broaden alliance to find their next Dupixent

    The deal carries a $1 billion upfront payment and tasks the two companies to develop long-acting antibody drugs that go after the same targets as their blockbuster anti-inflammation agent.

    By • Oct. 1, 2026
  • Close-up view of the Novo Nordisk logo mounted on the exterior wall of a building. The logo features a stylized blue Apis bull with a sun disk above its head, symbolizing the company's identity. The background shows a tan brick wall and part of a leafless tree in the foreground under a clear blue sky."
    Image attribution tooltip
    Alamy
    Image attribution tooltip
    Obesity drugs

    Novo to pay Hengrui up to $2.6B for a once-weekly obesity pill

    The deal, which hands Novo a challenger to Lilly’s market-leading Zepbound, comes as the Danish drugmaker looks to calm investor fears about its future.

    By • Sept. 29, 2026
  • An illustration of leukocytes attacking a cancer cell
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    AstraZeneca invests $2B in Summit, gaining ‘seat at the table’ for PD-1/VEGF drug push

    The equity investment comes alongside a deal to test Summit’s ivonescimab alongside potentially many AstraZeneca drugs — but doesn’t hand the pharmaceutical company any ownership rights.

    By • Sept. 29, 2026
  • An image of a periodic table entry for the chemical element lutetium
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Telix buys ITM in bid to create a ‘radiopharmaceutical powerhouse’

    Worth $1.65 billion up front, the deal combines two large pipelines and manufacturing networks, helping Telix potentially “corner the industry” for radiopharmaceuticals, one analyst wrote.

    By • Sept. 21, 2026
  • Close-up view of the Novo Nordisk logo mounted on the exterior wall of a building. The logo features a stylized blue Apis bull with a sun disk above its head, symbolizing the company's identity. The background shows a tan brick wall and part of a leafless tree in the foreground under a clear blue sky."
    Image attribution tooltip
    Alamy
    Image attribution tooltip
    Obesity drugs

    Novo partners with Orbis, deepening investment in oral peptide drugs

    The potentially $1.4 billion alliance will see the two companies collaborate on “macrocycles” that could yield oral treatments for cardiometabolic diseases.

    By • Sept. 17, 2026
  • A sign spelling Novartis hangs on the side of a building.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Novartis to pay $125M for blood-brain barrier crossing platform

    Proceeds from the deal, which hands Novartis global rights to a technology developed by Sironax, will help advance three candidates that the startup says have “best-in-class” potential.

    By • Sept. 16, 2026
  • A double exposure image of a glass flask in a laboratory with stock market information in the background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    This week in charts

    This week in charts: RA’s insatiable appetite, Novartis’ big slide and a reverse merger spree

    RA Capital has already participated in four biotech financings in September. Meanwhile, Janus Henderson has been the year's most prolific backer of biotech reverse merger deals, according to Gilmartin Group.

    By • Sept. 11, 2026
  • A low-angle, full shot of the Nasdaq MarketSite building in Times Square under a bright, overcast sky, featuring a large, curved blue digital billboard. The billboard displays a welcome message reading "Nasdaq Welcomes Faeth Therapeutics, June 23, 2026," alongside the Faeth logo and "FTH Nasdaq Listed."
    Image attribution tooltip
    Permission granted by Faeth Therapeutics
    Image attribution tooltip
    Deep Dive

    A booming business on Wall Street would love more biotechs to quietly die

    Once disparaged, reverse mergers have become so popular that some deal experts question whether there are enough quality shell companies to meet the demand.

    By • Sept. 10, 2026